8-K: Turn Therapeutics Secures Global Medline Partnership

Turn Therapeutics Inc. has entered into a multi-year Global Supply, Development, and License Agreement with Medline Industries, LP for its proprietary PermaFusion delivery platform.

Summary

• Turn Therapeutics Inc. (Turn) signed a Global Supply, Development, and License Agreement (the Agreement) with Medline Industries, LP (Medline) on October 27, 2025, with an effective date of October 23, 2025.
• The Agreement establishes a multi-year framework for collaboration on professional and consumer health products utilizing Turn's proprietary PermaFusion delivery platform.
• Medline will lead global commercialization and distribution across its professional and retail networks in more than 100 countries and territories.
• Turn will contribute its formulation expertise, intellectual property, and clinical development capabilities to the partnership.
• The initial term of the Agreement is three years, with automatic one-year renewals unless either party provides 120 days' prior written notice of non-renewal.
• Medline receives an exclusive, worldwide field-of-use license for Turn's 510(k) Clearance(s) for specific (redacted) applications, currently limited to one field.
• Turn grants Medline an exclusive right of first negotiation for any new product line extensions within the wound-care and over-the-counter (OTC) markets.
• The parties will engage in collaborative development programs for new products using Turn's antimicrobial and carrier technologies, with quarterly progress reviews.
• Medline and its designees are required to purchase all [***] (a key component/formulation) exclusively from Turn for any products or line extensions.
• Turn is required to publicly announce the Agreement within 72 hours of the October 23, 2025 effective date, providing Medline 48 hours for review and comment.

Sentiment

Score: 8

Explanation: The agreement with Medline is a substantial positive for Turn Therapeutics, providing global distribution, commercialization, and co-development opportunities for its proprietary technology. While specific financial terms are redacted and Medline's purchase obligations are not binding, the strategic value of partnering with a major industry player like Medline for market access and future product development is very high. The exclusivity clauses and mandatory purchase of key components from Turn further enhance the positive sentiment.

Positives

• Secures a global commercialization and distribution partner in Medline, the world's largest privately held medical-surgical products distributor, covering over 100 countries.
• Leverages Turn's proprietary PermaFusion delivery platform, intellectual property, and clinical development capabilities for broader market reach.
• Establishes a multi-year framework (initial 3 years, auto-renewing) providing long-term stability and potential revenue streams.
• Includes collaborative development programs for new products, indicating future growth potential beyond initial offerings.
• Medline is granted an exclusive right of first negotiation for wound-care and OTC line extensions, ensuring Turn's technology is prioritized within a major partner.
• Medline and its designees are restricted to purchasing a key component/formulation exclusively from Turn, ensuring a dedicated supply channel.
• Turn is indemnified by Medline for claims arising from Medline's breach of agreement, applicable laws, or gross negligence.

Negatives

• Specific financial terms, including product pricing and volume thresholds, are redacted, limiting transparency on immediate financial impact.
• Medline is not subject to any binding purchase obligations, and the contract is not a 'take-or-pay' agreement, meaning sales volumes are not guaranteed.
• Medline's commitment to commercial and development efforts is discretionary and not a guarantee of specific outcomes or levels of effort.
• Turn is responsible for maintaining a 98% fill rate on orders and delivering products within a 144-day lead time, which could pose operational challenges.
• Turn must maintain commercial general liability and products liability insurance of at least $3,000,000 per occurrence, adding to operational costs.
• Exclusivity for Medline is currently limited to a specific (redacted) field and does not extend to other substrates, potentially limiting Turn's independent market access in other areas.

Risks

• Failure by Medline to meet Volume Thresholds could lead to Turn losing exclusivity, allowing Turn to sell products non-exclusively but potentially diluting the value of the partnership.
• Medline's discretionary commercial efforts may not yield expected sales volumes or market penetration, impacting Turn's revenue.
• Operational challenges for Turn in meeting the 144-day lead time or 98% fill rate could lead to Medline terminating the agreement.
• The redacted nature of key financial terms (pricing, volume thresholds) introduces uncertainty regarding the agreement's financial upside.
• Reliance on Medline for global commercialization and distribution means Turn's market success is heavily dependent on Medline's performance and strategic priorities.
• Potential for disputes requiring arbitration under Illinois law and ICC rules, which can be costly and time-consuming.

Future Outlook

The agreement establishes a multi-year framework for supply and co-development activities, including manufacturing scale-up for PermaFusion-based formulations and co-branding of future products. The parties intend to collaborate on additional products, delivery formats, or substrates, and engage in development programs for new products in wound care, OTC, and other mutually agreed therapeutic or consumer categories.

Management Comments

• Turn and Medline will collaborate to develop, manufacture, and commercialize professional and consumer health products that leverage Turns proprietary PermaFusion delivery platform.
• Medline will lead global commercialization and distribution across its professional and retail networks in more than one hundred countries and territories, while Turn will contribute its formulation expertise, intellectual property, and clinical development capabilities.

Industry Context

This partnership positions Turn Therapeutics to significantly expand the global reach of its PermaFusion technology by leveraging Medline's extensive distribution network in the medical-surgical and consumer health product markets. It aligns with a broader industry trend of smaller biotech/medtech companies partnering with large distributors to accelerate market penetration and commercialization, particularly for novel delivery platforms in areas like wound care and OTC.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market expansion, and long-term growth due to global distribution and co-development, likely leading to positive share price movement.
• Employees: Potential for increased R&D activities and manufacturing scale-up, possibly leading to job creation or expansion of roles within Turn Therapeutics.
• Customers: Access to new and improved professional and consumer health products leveraging Turn's PermaFusion technology through Medline's extensive network.
• Suppliers: Increased demand for raw materials and components if product manufacturing scales up.

Next Steps

• Turn Therapeutics to publicly announce the agreement within 72 hours of October 23, 2025.
• Turn Therapeutics to provide Medline with a draft of the public announcement 48 hours prior for review.
• Turn Therapeutics to comply with the Universal Product Number (UPN) standard within 180 days of the Effective Date.
• Turn Therapeutics to add Medline and its Designee as an authorized manufacturer on the Supplier 510(k) Clearance for the [***].
• The parties will meet at least quarterly to review Development Program progress.
• The parties will work together to identify, evaluate, and develop new products utilizing Turn's proprietary technologies.
• Negotiate and execute separate written addenda for terms governing jointly developed products.

Key Dates

Recommendation

This agreement represents a transformative strategic partnership for Turn Therapeutics, securing a global leader in medical-surgical product distribution, Medline Industries, as its commercialization and development partner. The deal provides Turn with immediate access to over 100 countries and territories, significantly de-risking market entry and scale-up for its proprietary PermaFusion platform. The exclusive license and right of first negotiation for key markets, coupled with Medline's commitment to collaborative development and exclusive purchase of a core component, indicate strong validation of Turn's technology and a clear path to substantial revenue growth. While specific financial details are redacted, the strategic implications of this partnership are overwhelmingly positive, suggesting a strong upside potential for the stock.

Keywords

Turn Therapeutics, Medline Industries, PermaFusion, Global Supply Agreement, License Agreement, Medical Devices, Wound Care, OTC, Pharmaceuticals, Biotechnology, Commercialization, Distribution, SEC Filing, 8-K